Tislelizumab (i.v. 200mg) clinical trials

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

This study looks at combining a new medicine, futibatinib, with standard chemotherapy and immunotherapy (tislelizumab) for people with advanced bowel cancer. It checks how well it works and if it's safe as a first treatment, also exploring ways to predict who might benefit most.